3002

GZMB

granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1);GZMB;granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1)

C11|CTLA-1|T-cell serine protease 1-3E|cathepsin G-like 1|cytotoxic T-lymphocyte proteinase 2|cytotoxic serine protease B|fragmentin 2|fragmentin-2|granzyme B|human lymphocyte protein

14q11.2

protein-coding

AIMS: tumour-infiltrating forkhead box P3 (FoxP3+ ) regulatory T cells (T(regs) ) have stronger prognostic significance than cytotoxic CD8+ T cells in colorectal cancer (CRC). Because there is evidence that some tumour-infiltrating CD8+ T cells may be inactive, the present study aimed to investigate the prognostic significance of Granzyme B, one of the major effector molecules of T cells. METHODS AND RESULTS: A tissue microarray containing 963 CRCs was stained immunohistochemically for Granzyme B and the level of expression quantified by digital image analysis. Granzyme B expression was higher in tumours with microsatellite instability (P < 0.0001), a dense lymphocytic infiltrate (P < 0.0001) and location in the proximal colon (P = 0.009), but lower in tumours with vascular invasion (P = 0.007), perineural invasion (P =0.041) and positive nodal status (P < 0.001). Elevated expression of Granzyme B was associated with improved survival on univariate analysis (hazard ratio = 0.65; 95% confidence interval 0.51-0.84; P = 0.001), but not in a multivariate model that included stage, vascular invasion and FoxP3+ T(reg) cell density. CONCLUSIONS: Low expression of Granzyme B was associated with early signs of metastasis in CRC. The stronger prognostic significance of FoxP3+ T(regs) is in keeping with animal models that suggest these cells act as gatekeepers for the release of Granzyme B from CD8+ T cells.

BACKGROUND: Sentinel Lymph Node (SLN) status is strongly related to clinical outcome in melanoma patients. In this study we investigated the possible association between the presence of activated and/or suppressive tumour Infiltrating Lymphocytes (TILs) and SLN status in clinically stage I/II melanoma patients. METHODS: Diagnostic primary melanoma samples from 20 patients with a sentinel lymph node metastasis were compared to melanoma samples from 20 patients with a negative sentinel lymph node, who were matched for gender, age and Breslow thickness. Presence of activated Granzyme B positive (GrB+) TILs, presence of suppressive (FoxP3+) TILs and MHC class I antigen expression on tumour cells were analysed by immunohistochemistry. RESULTS: FoxP3 and MHC-I expression had no direct bearing on the presence of melanoma metastases in the SLN. Whereas the presence of activated GrB+ TILs in the primary melanoma had no predictive value for SLN status either, their absence was strongly associated with the presence of metastasis in the SLN (p=0.001). While both GrB+ and FoxP3+ TILs could be detected in SLN metastases, a majority did not display MHC-I expression. CONCLUSION: These data support a role for cytotoxic T cells in the prevention of early metastasis of melanoma to the draining lymph nodes.